Survivor t cells, survivor t cell population, and pharmaceutical composition

CA3317451A1Pending Publication Date: 2026-09-21NATIONAL CANCER CENTER(JP) +1
0 Cites 0 Cited by

Patent Information

Application Number
CA3317451
Authority / Receiving Office
CA · CA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-09
Filing Date
2025-01-08
Publication Date
2026-09-21

AI Technical Summary

Technical Problem

Cancer cells reprogram their metabolic systems to prioritize glucose uptake and lactate production, creating an immunosuppressive environment that impairs the function of antitumor T cells by depleting glucose and other nutrients, leading to dysfunction and exhaustion.

Method used

Development of T cells with enhanced glucose uptake ability, specifically through expression or enhanced expression of glucose transporters like GLUT3, to maintain functionality in low-glucose tumor environments, combined with chimeric antigen receptors (CARs) to enhance effector functions.

Benefits of technology

The modified T cells can maintain effective cytotoxic activity and cytokine production in low-glucose tumor microenvironments, overcoming metabolic competition with cancer cells and improving antitumor efficacy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides cells that are competitive with respect to cancer cells, without experiencing starvation or exhaustion, even in glucose-depleted environments. Specifically, the present disclosure provides survivor T cells with enhanced glucose uptake capacity. The T cells are modified so as to express a glucose transporter and / or configured such that the expression of a glucose transporter is enhanced. Also provided are a cell population including such cells, a pharmaceutical composition, and a treatment method.
Need to check novelty before this filing date? Find Prior Art